Polyfluoroalkyl substances (PFAS) are man-made chemicals developed in the 1940s that have been used in consumer products and manufacturing processes worldwide ever since. Incredibly resistant, PFAS have been used to make water-repellent clothing, stain resistant fabrics, nonstick cookware and cosmetics, but also in the production of mRNA vaccines and semiconductors. Their very resistance however means they do not break down naturally and remain in the environment forever and, most concerning, can accumulate in living organisms leading to harmful health effects in humans such as increased risk of cancer, high cholesterol levels and changes in liver enzymes. In this interview Henrik Hagemann tells us how Puraffinity is tackling the PFAS crisis.

Henrik Hagemann
CEO and Co-Founder, Puraffinity

Henrik Hagemann is CEO and Co-Founder of Puraffinity. A Verve Ventures portfolio company since 2019, Puraffinity develops engineered biomaterials that target Polyfluoroalkyl substances (PFAS) in contaminated water. In 2019, Henrik was on Forbes’ 30 Under 30 Europe list and MIT Tech Review’s 35 Under 35 Europe list. He has been part of the Diversity and Inclusion Steering group at the Royal Academy of Engineering for the last five years and together with co-founder Gabriella Santosa, strives to build Puraffinity into a startup with equity, diversity and inclusion at its heart. Henrik has a master’s in biomedical engineering from Imperial College London where he was an honoree of the President’s Medal for Outstanding Achievement.

Invest in Startups

As one of Europe’s most active venture capital investors, we grant qualified private investors access to top-tier European startups. With investments starting at EUR/CHF 10’000, you can build your own tailored portfolio over time and diversify across stages and sectors.